Related Experiment Video
Updated: Jul 31, 2025
Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors
Published on: January 20, 2023
Development of HSP90 inhibitors-SN38 conjugates for cancer treatment
Yuting Cao1, Qianqian Shen2, Mengyuan Ding1
1Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, PR China.
Abstract:
Presently, chemotherapy remains to be one of the most important therapeutic approaches for malignant tumors. Ligands based drug conjugates are showing considerable promise as potential therapeutic agents delivery systems for cancer. Here, a series of HSP90 inhibitors-SN38 conjugates were developed through cleavable linkers for tumor-specific delivery of SN38 and reducing its side effects. In vitro assays showed that these conjugates exhibited acceptable stability in PBS and plasma, appreciable HSP90 binding affinity, and potent cytotoxic abilities. Cellular uptake behaviors also indicated that these conjugates could selectively target cancer cells in a time-dependent manner via HSP90. Among them, compound 10b with a glycine linkage exhibits appreciable in vitro and in vivo pharmacokinetic profiles, and excellent in vivo antitumor activity in Capan-1 xenograft models, demonstrating the selective targeting and accumulation of the active payload at tumor sites. Above all, these results suggest that compound 10b has the potential as a potent anticancer drug, meriting further evaluation in the future.
Insights
New drug conjugates targeting HSP90 deliver the chemotherapy drug SN38 specifically to cancer cells, reducing side effects. Compound 10b shows promising in vivo antitumor activity and potential as a novel cancer therapeutic.
Area of Science:
- Oncology
- Medicinal Chemistry
- Drug Delivery Systems
Background:
- Chemotherapy is a cornerstone of cancer treatment, but systemic toxicity limits its efficacy.
- Ligand-based drug conjugates offer a promising strategy for targeted cancer therapy.
- Heat shock protein 90 (HSP90) is a validated target in oncology due to its role in cancer cell survival.
Purpose of the Study:
- To design and synthesize novel HSP90 inhibitor-SN38 conjugates for tumor-specific drug delivery.
- To evaluate the in vitro and in vivo efficacy of these conjugates.
- To assess the potential of compound 10b as a targeted anticancer agent.
Main Methods:
- Synthesis of HSP90 inhibitors-SN38 conjugates utilizing cleavable linkers.
- In vitro stability assays in PBS and plasma.
- HSP90 binding affinity and cytotoxicity assays.
- Cellular uptake studies to assess targeting efficiency.
- Pharmacokinetic profiling and in vivo antitumor efficacy studies in Capan-1 xenograft models.
Main Results:
- Conjugates demonstrated good stability and potent cytotoxic effects in vitro.
- Selective cancer cell targeting via HSP90 was confirmed through cellular uptake studies.
- Compound 10b exhibited favorable in vitro and in vivo pharmacokinetic profiles.
- Compound 10b showed significant in vivo antitumor activity in xenograft models, with payload accumulation at tumor sites.
Conclusions:
- HSP90 inhibitor-SN38 conjugates facilitate targeted delivery of SN38 to tumors, minimizing systemic toxicity.
- Compound 10b displays excellent in vitro and in vivo anticancer properties.
- Compound 10b represents a promising candidate for further development as a targeted cancer therapeutic.
More Related Videos
09:39Exploring Biomolecular Interaction Between the Molecular Chaperone Hsp90 and Its Client Protein Kinase Cdc37 using Field-Effect Biosensing Technology
Published on: March 31, 2022
06:51Studies of Chaperone-Cochaperone Interactions using Homogenous Bead-Based Assay
Published on: July 21, 2021
